- •Liver cirrhosis accounts for more than one million deaths each year worldwide.
- •Of 2557 patients with chronic hepatitis observed in 2014, 32.6% had cirrhosis.
- •HCV was responsible of 58.6% of cases, HBV of 17.6% and alcohol abuse of 16.0%.
- •HCV and alcohol cases significantly decreased in the last two decades in Italy.
Abbreviations:HBV (hepatitis B virus), HCV (hepatitis C virus), HCC (hepatitis delta virus (HDV) hepatocellular carcinoma), ISTAT (Italian Institute of Statistic), NAFLD (non-alcoholic fatty liver disease), NASH (non-alcoholic steatohepatitis)
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:Subscribe to European Journal of Internal Medicine
- Liver cirrhosis mortality in 187 countries between 1980 and 2010: a systematic analysis.BMC Med. 2014; 12: 145
- The burden of liver disease in Europe: a review of available epidemiological data.J Hepatol. 2013; 58: 593-608
- Occurrence of Australia antigen in chronic hepatitis in Italy.Gastroenterology. 1972; 63: 482-485
- Epidemiologic patterns of infection with the hepatitis B virus-associated delta agent in Italy.Am J Epidemiol. 1983; 117: 223-229
- Pathogenic factors in cirrhosis with and without hepatocellular carcinoma: a multicenter Italian study.Hepatology. 1994; 20: 1225-1230
- Characteristics of liver cirrhosis in Italy: results from a multicenter national study.Dig Liver Dis. 2004; 36: 56-60
- Mortality data.2005
- The changing pattern of hepatitis B virus infection over the past three decades in Italy.Dig Liver Dis. 2005; 37: 622-627
- Impact of comorbidities on the severity of chronic hepatitis B at presentation.World J Gastroenterol. 2012; 18: 1616-1621
- Epidemiology of acute and chronic hepatitis B and delta over the last 5 decades in Italy.World J Gastroenterol. 2014; 20: 7635-7643
- Hepatitis C virus infection in an endemic area of southern Italy 14 years later: evidence for a vanishing infection.Dig Liver Dis. 2013; 45: 403-407
- What is the criterion for differentiating chronic hepatitis from compensated cirrhosis? A prospective study comparing ultrasonography and percutaneous liver biopsy.J Hepatol. 1997; 27: 979-985
- Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the liver.J Hepatol. 2001; 35: 421-430
- Clinical diagnosis of primary biliary cirrhosis: a classification based on major and minor criteria.Hepatogastroenterology. 1983; 30: 178-182
- International autoimmune hepatitis group report: review of criteria for diagnosis of autoimmune hepatitis.J Hepatol. 1999; 31: 929-938
- Genotypic/phenotypic correlations in genetic hemochromatosis: evolution of diagnostic criteria.Gastroenterology. 1998; 114: 319-323
- Diagnosis and phenotypic classification of Wilson disease.Liver Int. 2003; 23: 139-142
- Prediction of risk of liver disease by alcohol intake, sex, and age: a prospective population study.Hepatology. 1996; 23: 1025-1029
- Alcoholic liver disease: proposed recommendations for the American College of Gastroenterology.Am J Gastroenterol. 1998; 93: 2022-2036
- Histological grading and staging of chronic hepatitis.J Hepatol. 1995; 22: 696-699
- An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group.Hepatology. 1996; 24: 289-293
- Takahashi H. Ishak versus METAVIR: terminology, convertibility and correlation with laboratory changes in chronic hepatitis C, liver biopsy. 978-953-307-644-7 InTech, 2011 ([Available from: http://www.intechopen.com/books/liver-biopsy/ishak-versus-metavir-terminology-convertibility-and-correlation-with-laboratory-changes-in-chronic-h])
- Performance of transient elastography for the staging of liver fibrosis in patients with chronic hepatitis B: a meta-analysis.PLoS One. 2012; 7: e44930
- Liver stiffness measurement using XL probe in patients with nonalcoholic fatty liver disease.Am J Gastroenterol. 2012; 107: 1862-1871
- Liver fibrosis in human immunodeficiency virus/hepatitis C virus coinfection: diagnostic methods and clinical impact.World J Hepatol. 2015; 7: 2510-2521
- Incidents, clynical presentations and mortality of liver cirrhosis in southern Sweden: a 10-year population based study.Aliment Pharmacol Ther. 2016; 43: 1330-1339
- The importance of HCV on the burden of chronic liver disease in Italy: a multicenter prevalence study of 9,997 cases.J Med Virol. 2005; 75: 522-527
- Prevalence, risk factors, and genotype distribution of hepatitis C virus infection in the general population: a community-based survey in southern Italy.Hepatology. 1997; 26: 1006-1011
- Predicted effects of treatment for HCV infection vary among European countries.Gastroenterology. 2012; 143: 974-985
- Efficacy and safety of 12 weeks versus 18 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin for hepatitis C virus genotype 1 infection in previously untreated patients with cirrhosis and patients with previous null response with or without cirrhosis (C-WORTHY): a randomised, open-label phase 2 trial.Lancet. 2015; 385: 1075-1086
- Ledipasvir-sofosbuvir with or without ribavirin to treat patients with HCV genotype 1 infection and cirrhosis non-responsive to previous protease-inhibitor therapy: a randomised, double-blind, phase 2 trial (SIRIUS).Lancet Infect Dis. 2015; 15: 397-404
- Ledipasvir and sofosbuvir in patients with genotype 1 hepatitis C virus infection and compensated cirrhosis: an integrated safety and efficacy analysis.Hepatology. 2015; 62: 79-86
- Efficacy and safety of ombitasvir, paritaprevir, and ritonavir in an open-label study of patients with genotype 1b chronic hepatitis C virus infection with and without cirrhosis.Gastroenterology. 2015; 149: 971-980
- Ombitasvir, paritaprevir co-dosed with ritonavir, dasabuvir, and ribavirin for hepatitis C in patients co-infected with HIV-1: a randomized trial.JAMA. 2015; 313: 1223-1231
- Ledipasvir and sofosbuvir for HCV in patients coinfected with HIV-1.N Engl J Med. 2015; 373: 705-713
- Daclatasvir plus sofosbuvir for HCV in patients coinfected with HIV-1.N Engl J Med. 2015; 373: 714-725
- Gender differences in chronic HBsAg carriers in Italy: evidence for the independent role of male sex in severity of liver disease.J Med Virol. 2015; 87: 1899-1903
☆Financial support: an unrestricted grant for the study was provided by Gilead.